头孢西丁和头孢替坦对小鼠偶然分枝杆菌感染的活性。
Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in mice.
作者信息
Saito H, Sato K, Jin B W
出版信息
Antimicrob Agents Chemother. 1984 Aug;26(2):270-1. doi: 10.1128/AAC.26.2.270.
Abstract
Mice inoculated intravenously with Mycobacterium fortuitum 18367 were treated subcutaneously with cefoxitin or cefotetan once daily for 4 weeks, beginning 24 h after challenge. Both drugs suppressed spinning disease, and both reduced the severity of renal lesions and the number of organisms in the kidneys and liver but not in the lungs or spleen. These therapeutic effects were dose-dependent.
摘要
用偶然分枝杆菌18367静脉接种的小鼠，在攻击后24小时开始，每天皮下注射头孢西丁或头孢替坦，持续4周。两种药物都抑制了旋转病，并且都减轻了肾脏病变的严重程度以及肾脏和肝脏中的细菌数量，但对肺或脾脏中的细菌数量没有影响。这些治疗效果是剂量依赖性的。
相似文献
1
Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in mice.头孢西丁和头孢替坦对小鼠偶然分枝杆菌感染的活性。
Antimicrob Agents Chemother. 1984 Aug;26(2):270-1. doi: 10.1128/AAC.26.2.270.
2
Cefoxitin therapy for Mycobacterium fortuitum bacteremia with associated granulomatous hepatitis.
South Med J. 1984 Mar;77(3):381-4. doi: 10.1097/00007611-198403000-00029.
3
Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.基于体外药敏结果对偶然分枝杆菌和龟分枝杆菌所致非肺部感染的治疗。
J Infect Dis. 1985 Sep;152(3):500-14. doi: 10.1093/infdis/152.3.500.
4
Preliminary report on a comparative trial of cefotetan and cefoxitin in the treatment of urinary tract infections.头孢替坦与头孢西丁治疗尿路感染的对比试验初步报告
J Antimicrob Chemother. 1983 Jan;11 Suppl:227-32. doi: 10.1093/jac/11.suppl_a.227.
5
Comparison of cefotetan and cefoxitin prophylaxis for abdominal and vaginal hysterectomy.
Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):706-9. doi: 10.1016/s0002-9378(16)44531-x.
6
Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections.头孢替坦与头孢西丁治疗急性妇产科感染的多中心比较
Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):722-7. doi: 10.1016/s0002-9378(16)44535-7.
7
Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections.
Am J Surg. 1988 May 31;155(5A):56-60. doi: 10.1016/s0002-9610(88)80214-9.
8
Comparison of cefotetan and cefoxitin as prophylaxis in cesarean section.头孢替坦与头孢西丁在剖宫产术中预防性应用的比较。
Am J Obstet Gynecol. 1986 Apr;154(4):951-4. doi: 10.1016/0002-9378(86)90496-5.
9
A multicenter comparative study of cefotetan once daily and cefoxitin thrice daily for the treatment of infections of the skin and superficial soft tissue.
Am J Surg. 1988 May 31;155(5A):91-5. doi: 10.1016/s0002-9610(88)80221-6.
10
Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.头孢菌素治疗腹腔内感染。头孢替坦、拉氧头孢和头孢西丁的多中心随机对照研究。
Am J Surg. 1988 May 31;155(5A):61-6. doi: 10.1016/s0002-9610(88)80215-0.
本文引用的文献
1
Atypical acid-fast bacilli. II. Mycobacterium fortuitum: bacteriologic characteristics and pathogenicity for laboratory animals.非典型抗酸杆菌。II. 偶然分枝杆菌：实验室动物的细菌学特征及致病性
Am Rev Tuberc. 1957 Jul;76(1):108-22. doi: 10.1164/artpd.1957.76.1.108.
2
Bacterial localisation in the kidney with particular reference to Pseudomonas pyocyanea.细菌在肾脏中的定位，特别提及绿脓杆菌。
J Pathol Bacteriol. 1952 Oct;64(4):857-64. doi: 10.1002/path.1700640417.
3
Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.磺胺对偶然分枝杆菌和龟分枝杆菌的活性。
Rev Infect Dis. 1981 Sep-Oct;3(5):898-904. doi: 10.1093/clinids/3.5.898.
4
Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.具有抗假单胞菌活性的氨基糖苷类药物与头孢菌素之间的协同作用：相互作用指数和杀菌曲线法
Antimicrob Agents Chemother. 1982 Nov;22(5):743-52. doi: 10.1128/AAC.22.5.743.
5
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.N-甲酰亚胺硫霉素对革兰氏阳性和革兰氏阴性需氧及厌氧菌的体外比较活性及其β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1982 Jan;21(1):180-7. doi: 10.1128/AAC.21.1.180.
6
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.MK0787（N-亚胺甲酰硫霉素）：体内外活性评估
Antimicrob Agents Chemother. 1980 Jun;17(6):993-1000. doi: 10.1128/AAC.17.6.993.
7
A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.N-甲酰亚胺基硫霉素（MK0787）与其他近期研发的β-内酰胺衍生物抗菌活性的比较。
Antimicrob Agents Chemother. 1982 Aug;22(2):302-7. doi: 10.1128/AAC.22.2.302.
8
Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.新型广谱头孢菌素所选择的新型耐药性：一个值得关注的问题。
J Infect Dis. 1983 Mar;147(3):585-9. doi: 10.1093/infdis/147.3.585.
9
Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.哌拉西林治疗伴有铜绿假单胞菌耐药获得及临床复发情况的临床试验
Antimicrob Agents Chemother. 1980 Jul;18(1):167-70. doi: 10.1128/AAC.18.1.167.
10
Piperacillin therapy for serious bacterial infections.
Am J Med. 1980 Aug;69(2):255-61. doi: 10.1016/0002-9343(80)90386-1.
Zotero 插件